Photo by Martin Lopez on Pexels.com

Agilent Technologies Stock (A) Rose More Than 7% Today After the Company Reported Fourth Quarter Revenue of $1.29 Billion

Press Release

Agilent Technologies Reports Fourth-Quarter Fiscal Year 2018 Financial Results

Agilent delivers outstanding quarter wrapping up an excellent 2018

SANTA CLARA, Calif., November 19, 2018

Fourth Quarter

Q4 revenue of $1.29 billion, representing growth of 9 percent with core revenue growth of 9 percent(1)
Q4 GAAP net income of $195 million, or $0.61 per share
Q4 non-GAAP net income of $262 million, or $0.81 per
share(2), an increase of 21 percent from 2017
Board authorizes new $1.75 billion share repurchase program
Full Year

Full year revenue of $4.91 billion, representing 10 percent growth and core growth of 7 percent(1)
Full year GAAP net income of $316 million, or $0.97 per share
Full year non-GAAP net income of $907 million, or $2.79 per share(2), an increase of 18 percent from 2017
Outlook

Fiscal year 2019 revenue guidance of $5.13 billion to $5.17 billion, representing growth of 4.4 to 5.2 percent and core growth of 5.0 to 5.5 percent(1). Non-GAAP earnings guidance of $3.00 to $3.05 per share(3)
First-quarter fiscal year 2019 revenue guidance of $1.265 billion to $1.280 billion, representing growth of 4.4 to 5.7 percent and core revenue growth of 4.5 to 5.5 percent(1). Non-GAAP earnings guidance of $0.71 to $0.73 per share(3)
Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.29 billion for the fourth-quarter ended October 31, 2018, up 9 percent year over year (up 9 percent on a core basis(1)).

Fourth-quarter GAAP net income was $195 million, or $0.61 per share. Last year’s fourth-quarter GAAP net income was $177 million, or $0.54 per share.

“The Agilent team delivered an outstanding quarter to wrap up the fiscal year with revenues and earnings per share ahead of expectations,” said Mike McMullen, Agilent CEO and President. “Our performance this quarter caps off an excellent 2018 as we achieved our highest annual core growth rate and profitability since becoming a stand-alone life sciences company in 2014.”

“During the quarter we continued our investment in growth introducing new and differentiated products and services,” continued McMullen. “We leveraged our strong balance sheet completing several acquisitions to further strengthen our portfolio. We also returned over $600 million to shareholders through stock buybacks and dividends this year.

“We enter fiscal 2019 with momentum. Our focus remains on executing our shareholder value creation model to deliver superior earnings growth.”

Financial Highlights

Life Sciences and Applied Markets Group

Fourth-quarter revenue of $597 million from Agilent’s Life Sciences and Applied Markets Group (LSAG) grew 8 percent year over year (up 9 percent on a core basis(1)), with broad-based strength across major end markets, platforms and regions. LSAG’s operating margin for the quarter was 25.9 percent. Full-year revenue of $2.3 billion grew 9 percent year over year (up 7 percent on a core basis(1)). LSAG’s operating margin for the year was 24.1 percent.

Agilent CrossLab Group

Fourth-quarter revenue of $441 million from Agilent CrossLab Group (ACG) grew 9 percent year over year (up 9 percent on a core basis(1)). Demand was excellent across both services and consumables. ACG’s operating margin for the quarter was 24.7 percent. Full-year revenue of $1.7 billion grew 11 percent year over year (up 8 percent on a core basis(1)). ACG’s operating margin for the year was 23.3 percent.

Diagnostics and Genomics Group

Fourth-quarter revenue of $256 million from Agilent’s Diagnostics and Genomics Group (DGG) grew 9 percent year over year (up 5 percent on a core basis(1)) led by pharma growth and strong demand for genomics and NASD products. DGG’s operating margin for the quarter was 23.3 percent. Full-year revenue of $943 million grew 10 percent year over year (up 5 percent on a core basis(1)). DGG’s operating margin for the year was 18.9 percent.

2019 First Quarter and Full Year Outlook

For fiscal year 2019, Agilent expects revenue of $5.13 billion to $5.17 billion, representing growth of 4.4 to 5.2 percent and core growth of 5.0 to 5.5 percent(1). Full-year 2019 non-GAAP earnings of $3.00 to $3.05 per share(3). The guidance is based on October 31, 2018 currency exchange rates.

Agilent expects first-quarter 2019 revenue in the range of $1.265 billion to $1.280 billion, representing growth of 4.4 to 5.7 percent and core revenue growth of 4.5 to 5.5 percent(1). First-quarter 2019 non-GAAP earnings are expected to be in the range of $0.71 to $0.73 per share(3).

New Share Repurchase Program

Agilent’s Board of Directors approved a new share repurchase program authorizing the purchase of up to $1.75 billion of common stock. The 2018 share repurchase program commences on November 21, 2018, replacing the previous program.

The number of shares to be repurchased and the timing of any repurchases will depend on factors such as the share price, economic and market conditions, and corporate and regulatory requirements. The share repurchase program may be suspended, amended or discontinued at any time.

Conference Call

Agilent’s management will present more details about its fourth-quarter FY2018 financial results on a conference call with investors today at 1:30 p.m. (Pacific Time). This event will be webcast live in listen-only mode. Listeners may log on at www.investor.agilent.com and select “Q4 2018 Agilent Technologies Inc. Earnings Conference Call” in the “News & Events Calendar of Events” section. The webcast will remain available on the company’s website for 90 days.

Additional information regarding financial results can be found at www.investor.agilent.com by selecting “Financial Results” in the “Financial Information” section.

In addition, a telephone replay of the conference call will be available at approximately November 19, 2018 at 4:30 p.m. (Pacific Time) after the call and through November 26 by dialing +1 855-859-2056 (or +1 404-537-3406 from outside the United States) and entering pass code 6519506.

# # #

Glenford Robinson

I am a Clinical Lab Scientist, entrepreneur, investor and trader (stocks and Forex). I enjoy writing and publishing articles online.

Check Also

Pfizer Stock (PFE) on Investor Radar Today, Nov 23, 2018, After FDA Approval of Its Acute Myeloid Leukemia Drug Daurismo (glasdegib)

The FDA granted the approval of Daurismo to Pfizer...

Restore Bio Inc., Stock (TORC) Up Over 6% On Positive FDA Phase 2b Trial News for RTB101 Potential in Reducing Incidence of Respiratory Track Infections in Elderly Patients and Third Quarter 2018 Financial Results

Restorbio Reports Third Quarter 2018 Financial Results Nov 13, 2018 and FDA phase 2b postive news

Seattle Genetics Stock (SGEN) Rose 6% on FDA Approval News.

SGEN in the Spotlight Again on FDA Approval of First-line Treatment for T-Cell Lymphoma...

Two ICO Issuers Settle SEC Registration Charges, Agree to Register Tokens as Securities

SEC Imposed civil penalties on ICO security issuers who did not register their ICO offerings with the SEC...

Bitcoin Crash Sets Stage for Minting New Millionaires

Are you ready to become a Cryptocurrency Millionaire?

EURUSD Currently Displaying Short-Term Bullish Character…Be Very Cautious…A Reversal Could be Eminent at Any Moment!

Eurozone Weak Economy Taking a Toll on EURUSD Currency Pair

Possible US Central Bank Cryptocurrency Coming Soon! Vice President of Research, Federal Reserve Bank Hinted…

Federal Reserve Central Bank Cryptocurrency Possibly Coming Soon!

%d bloggers like this: